Duration of suppression of bone turnover following treatment with zoledronic acid in men with metastatic castration-resistant prostate cancer

AIM: Zoledronate is approved for use every 3 weeks in men with bone metastases from castrate-resistant prostate cancer (CRPC) but the basis for such frequency is unclear. METHODS: In men with bone metastasis from CRPC we measured the markers of bone turnover - urine and serum telopeptides before the...

Descripción completa

Detalles Bibliográficos
Autores principales: Niraula, Saroj, Templeton, Arnoud J, Vera-Badillo, Francisco, Dodd, Anna, Nugent, Zoann, Joshua, Anthony M, Tannock, Ian F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Science Ltd 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5729592/
https://www.ncbi.nlm.nih.gov/pubmed/29255625
http://dx.doi.org/10.4155/fsoa-2017-0094

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5729592/
https://www.ncbi.nlm.nih.gov/pubmed/29255625
http://dx.doi.org/10.4155/fsoa-2017-0094

Ejemplares similares